Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099264 | 0.94 | CRBN (0.51) | DDB1CRBNAAK1PDE10ASPR | |
| SCHEMBL22835210 | 0.90 | CRBN (0.52) | DDB1CRBNAAK1PDE10A | |
| SCHEMBL26101821 | 0.89 | CRBN (0.50) | DDB1CRBNAAK1 | |
| SCHEMBL22835967 | 0.86 | CRBN (0.48) | DDB1CRBNAAK1PDE10A | |
| SCHEMBL26099285 | 0.84 | DDB1 (0.46) | DDB1CRBNUSP30GPR119 | |
| SCHEMBL26101406 | 0.84 | DDB1 (0.46) | DDB1CRBNUSP30GPR119 | |
| SCHEMBL26101026 | 0.83 | CRBN (0.54) | DDB1CRBNGPR119 | |
| SCHEMBL26101989 | 0.82 | CRBN (0.48) | DDB1CRBN | |
| SCHEMBL21997940 | 0.81 | DDB1 (0.59) | DDB1CRBNMCHR1 | |
| SCHEMBL26100759 | 0.81 | DDB1 (0.48) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | DDB1 2403/4885CRBN 111/4885AAK1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.